Other Sources Fund Early-Stage Alzheimer’s Research As Pharma Favors Later Stages
Could Approval Of Biogen’s Aducanumab Improve Risk Tolerance?
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.
